A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects
Author:
Affiliation:
1. Daiichi Sankyo Pharma Development; Edison NJ USA
2. Worldwide Clinical Trials; San Antonio TX USA
3. Daiichi Sankyo Development Ltd; Gerrards Cross UK
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13658/fullpdf
Reference35 articles.
1. Review of the cost of venous thromboembolism;Fernandez;Clinicoecon Outcomes Res,2015
2. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association;Go;Circulation,2013
3. Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines;Guyatt;Chest,2012
4. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013;GBD 2013 Mortality and Causes of Death Collaborators;Lancet,2015
5. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association;Mozaffarian;Circulation,2015
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach;Circulation;2024-09-10
2. Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives;Journal of Clinical Medicine;2024-03-28
3. Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study;Journal of Thrombosis and Haemostasis;2023-10
4. Brain Expression of CPB2 and Effects of Cpb2 Deficiency in Mouse Models of Behavior;Thrombosis and Haemostasis;2023-08-02
5. Fibrinolytic Status and Risk of Death After Acute Pulmonary Embolism;Clinical and Applied Thrombosis/Hemostasis;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3